Sunesis Pharmaceuticals (NASDAQ:SNSS) Shares Gap Down to $0.84
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS)’s share price gapped down prior to trading on Thursday . The stock had previously closed at $0.96, but opened at $0.84. Sunesis Pharmaceuticals shares last traded at $0.81, with a volume of 6,041,285 shares changing hands.
A number of research analysts recently issued reports on the company. ValuEngine raised XOMA from a “sell” rating to a “hold” rating in a report on Friday, May 24th. HC Wainwright set a $267.00 price target on Sarepta Therapeutics and gave the company a “buy” rating in a report on Monday, June 17th. Zacks Investment Research cut HEXO from a “hold” rating to a “sell” rating in a report on Wednesday, May 15th. Finally, Cowen reaffirmed a “hold” rating on shares of Sunesis Pharmaceuticals in a report on Sunday, June 16th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $3.08.
The company’s fifty day moving average price is $0.75. The firm has a market capitalization of $53.67 million, a price-to-earnings ratio of -1.08 and a beta of 2.76.
A number of large investors have recently made changes to their positions in the business. Algert Global LLC acquired a new stake in shares of Sunesis Pharmaceuticals in the 1st quarter valued at $25,000. Fosun International Ltd acquired a new stake in shares of Sunesis Pharmaceuticals in the 1st quarter valued at $863,000. Finally, Aisling Capital Management LP raised its holdings in shares of Sunesis Pharmaceuticals by 192.3% in the 1st quarter. Aisling Capital Management LP now owns 7,600,000 shares of the biopharmaceutical company’s stock valued at $9,234,000 after purchasing an additional 5,000,000 shares in the last quarter. 43.10% of the stock is owned by hedge funds and other institutional investors.
Sunesis Pharmaceuticals Company Profile (NASDAQ:SNSS)
Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.
Featured Story: Should You Consider an Index Fund?
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.